The anti-tumor activity of CDK2 inhibition alone or in combination with other anti-cancer agents in human cancers

被引：0
|
作者：
Chen, Yaoyu
Chen, Jinhong
Guo, Yali
Pang, Wei
Zhou, Tingru
Liu, Xipan
Schomer, Nathan
Li, Fang
Liang, Jiaqi
Sheng, Qing
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B173
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B173
引用
收藏
页数：2
相关论文
共 50 条
  • [21] POTENTIAL ANTI-TUMOR AGENTS .9. SYNTHESIS AND ANTI-TUMOR ACTIVITY OF 2 ANALOGS OF KETOCAINE
    ANDREANI, A
    SCAPINI, G
    GALATULAS, I
    BOSSA, R
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1983, 72 (07) : 814 - 815
  • [22] Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
    Chohan, Tahir Ali
    Qian, Haiyan
    Pan, Youlu
    Chen, Jian-Zhong
    CURRENT MEDICINAL CHEMISTRY, 2015, 22 (02) : 237 - 263
  • [23] Combination of photodynamic therapy with anti-cancer agents
    Zuluaga, M. -F.
    Lange, N.
    CURRENT MEDICINAL CHEMISTRY, 2008, 15 (17) : 1655 - 1673
  • [24] THE LOGISTICS OF BROADER PRE-CLINICAL EVALUATION OF POTENTIAL ANTI-CANCER AGENTS WITH REFERENCE TO ANTI-TUMOR ACTIVITY AND TOXICITY OF MITOZOLOMIDE
    BIBBY, MC
    DOUBLE, JA
    WAHED, IA
    HIRBAWI, N
    BAKER, TG
    BRITISH JOURNAL OF CANCER, 1988, 58 (02) : 139 - 143
  • [25] Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
    Naing, Aung
    Pant, Shubham
    Infante, Jeffrey
    Papadopoulos, Kyriakos
    Autio, Karen
    Wong, Deborah
    Ott, Patrick
    Falchook, Gerald
    Patel, Manish
    Whiteside, Melinda
    Colen, Rivka
    Bendell, Johanna
    Bauer, Todd
    Janku, Filip
    Javle, Milind
    Tannir, Nixar
    Oft, Martin
    Chan, Ivan
    Rasco, Drew
    Hong, David
    Patnaik, Amita
    Moore, Kathen
    Korn, Michael
    Van-Vlasselaer, Peter
    Brown, Gail
    BJU INTERNATIONAL, 2016, 118 : 25 - 25
  • [26] Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
    Naing, A.
    Papadopoulos, K. P.
    Autio, K. A.
    Ott, P. A.
    Patel, M. R.
    Wong, D. J.
    Falchook, G.
    Pant, S.
    Whiteside, M.
    Rasco, D.
    Patnaik, A.
    Bendell, J. C.
    Bauer, T. M.
    Colen, R. R.
    Hong, D.
    Van Vlasselaer, P.
    Brown, G. L.
    Oft, M.
    Tannir, N.
    Infante, J. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [27] EFFECT OF HYPERTHERMIA ALONE AND IN COMBINATION WITH ANTI-CANCER AGENTS ON P388 LEUKEMIA
    ADWANKAR, MK
    CHITNIS, MP
    INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS, 1979, 16 (01): : 29 - 29
  • [28] Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST
    Inga-Marie Schaefer
    Matthew L. Hemming
    Meijun Z. Lundberg
    Matthew P. Serrata
    Isabel Goldaracena
    Ninning Liu
    Peng Yin
    Joao A. Paulo
    Steven P. Gygi
    Suzanne George
    Jeffrey A. Morgan
    Monica M. Bertagnolli
    Ewa T. Sicinska
    Chen Chu
    Shanshan Zheng
    Adrian Mariño-Enríquez
    Jason L. Hornick
    Chandrajit P. Raut
    Wen-Bin Ou
    George D. Demetri
    Sinem K. Saka
    Jonathan A. Fletcher
    British Journal of Cancer, 2022, 127 : 2072 - 2085
  • [29] Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST
    Schaefer, Inga-Marie
    Hemming, Matthew L.
    Lundberg, Meijun Z.
    Serrata, Matthew P.
    Goldaracena, Isabel
    Liu, Ninning
    Yin, Peng
    Paulo, Joao A.
    Gygi, Steven P.
    George, Suzanne
    Morgan, Jeffrey A.
    Bertagnolli, Monica M.
    Sicinska, Ewa T.
    Chu, Chen
    Zheng, Shanshan
    Marino-Enriquez, Adrian
    Hornick, Jason L.
    Raut, Chandrajit P.
    Ou, Wen-Bin
    Demetri, George D.
    Saka, Sinem K.
    Fletcher, Jonathan A.
    BRITISH JOURNAL OF CANCER, 2022, 127 (11) : 2072 - 2085
  • [30] MUTAGENIC ACTIVITY OF NITROSOUREA ANTI-TUMOR AGENTS
    FRANZA, BR
    OESCHGER, NS
    OESCHGER, MP
    SCHEIN, PS
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1980, 65 (01) : 149 - 154
12345